In preclinical trials, anti-CCL2 in combination with BRAF-targeted therapy reduced tumour sizes [122], as did anti-CXCR4 peptides when used alongside PD-1 [129], and both demonstrated a reduction in MDSCs and T-regs. Here, PDCD1 is linked to neoplasm.